Judith Derdelinckx

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7611367/publications.pdf

Version: 2024-02-01

1478505 1720034 9 134 6 7 citations h-index g-index papers 9 9 9 205 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future. Frontiers in Immunology, 2021, 12, 624685.	4.8	15
2	Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. International Journal of Molecular Sciences, 2021, 22, 7536.	4.1	6
3	Neuromyelitis Optica Spectrum Disorders in Africa. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	8
4	HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients. Cells, 2020, 9, 2703.	4.1	0
5	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. Journal of Neuroinflammation, 2019, 16, 167.	7.2	20
6	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open, 2019, 9, e030309.	1.9	63
7	Shuttling Tolerogenic Dendritic Cells across the Blood–Brain Barrier In Vitro via the Introduction of De Novo C–C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. Frontiers in Immunology, 2018, 8, 1964.	4.8	8
8	GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use. Methods in Molecular Biology, 2016, 1428, 139-150.	0.9	12
9	Towards a dendritic cell-based vaccine for the treatment of multiple sclerosis (MS): interim safety data of the first dose cohort of the MS-tolDC phase I clinical trial. Frontiers in Neuroscience, 0, 12, .	2.8	2